Advaxis announces first patient dosed in Phase 1/2 ADXS-HPV Advaxis announced that the first patient has been dosed in a Phase 1/2 “window of opportunity” study. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the “window” of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors. This investigator-initiated clinical study is designed to enroll 25 patients with human papillomavirus-positive stage II-IV squamous cell carcinoma of the oropharynx who are scheduled to undergo TORS. The primary objective of this study is to assess the safety, efficacy, and immunogenicity of ADXS-HPV in this patient population prior to undergoing surgery.
Advaxis to receive $1.6M through NJ NOL Program Advaxis announced the company has received preliminary approval for a $1.8M tax credit from the New Jersey Technology Business Tax Certificate Transfer, or NOL, Program for the year 2015. The company anticipates it will be able to transfer this credit and receive approximately $1.6M in cash in December.